

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

CLAIMS

1. A composition in form of solution for use in an aerosol inhaler, the composition comprising an active material, a propellant containing a hydrofluoroalkane (HFA), a cosolvent, optionally a low volatility component characterized in that the propellant consists of a mixture of HFA 227 and HFA 134a.
2. A composition according to claim 1, wherein the ratio of HFA 227/HFA 134a ranges from 10:90 to 90:10.
3. A composition according to claim 1 or 2, wherein the low volatility component has a vapour pressure at 25°C lower than 0.1 kPa.
4. A composition according to claim 3, wherein the low volatility component has a vapour pressure at 25°C lower than 0.05 kPa.
5. A composition according to any preceding claim, wherein the cosolvent has a vapour pressure at 25°C lower than 3 kPa.
6. A composition according to any preceding claim, wherein the cosolvent has a vapour pressure at 25°C lower than 5 kPa.
7. A composition according to any preceding claim, wherein the cosolvent is an alcohol.
8. A composition according to any preceding claim, wherein the low volatility component includes a glycol, oleic acid or isopropyl myristate.
9. A composition according to any preceding claim,

wherein the composition includes not more than 20% by weight of the low volatility component.

10. A composition according to any preceding claim, wherein the composition includes at least 0.2% by weight
5 of the low volatility component.

11. A composition according to any preceding claim, the composition being such that, on actuation of the aerosol inhaler in use, the MMAD of the aerosol particles is not less than 2 μm .

10 12. An aerosol inhaler containing a solution composition comprising an active material, a propellant containing one or more hydrofluoroalkane, a cosolvent and optionally a low volatility component wherein the particle MMAD is greater than 2 μm and the fine particle dose ($< 4.7 \mu\text{m}$)
15 is $> 30\%$.

13. An aerosol inhaler according to claim 12 wherein the particle MMAD is greater than 2 μm and the fine particle dose ($< 4.7 \mu\text{m}$) is $> 40\%$.

14. An aerosol inhaler according to claims 12 and 13
20 wherein the particle MMAD is greater than 2 μm and the fine particle dose ($< 4.7 \mu\text{m}$) is $> 50\%$.

15. An aerosol inhaler according to claims 12 to 14 having a chamber volume ranging from 25 to 50 μl yielding an increase of FPD compared to inhalers having chamber
25 volumes larger than 50 μl .

16. An aerosol inhaler according to claims 12 to 15 containing the compositions of claims 1-11.

17. An aerosol inhaler according to claims 12 to 16

having part or all of the internal surfaces consisting of stainless steel, anodised aluminium or lined with an inert organic coating.

18. A delivery system for the administration of drugs to the lung consisting of aerosol drug solution in a mixture of 134a and 227 HFA propellants, a cosolvent and optionally a low volatility component, in an aerosol inhaler having a chamber volume ranging from 25 to 50 μ l.